Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. (not Streamex Corp.) on January 17, 2023, covering events occurring on January 10, 2023. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard operating financial results. Key metrics from the transaction include:
- Total Consideration Raised: $1,254,884.28
- Common Shares Sold: 2,178,316 shares
- Purchase Price per Share: $0.57608
- Warrants Issued: Warrants to purchase up to 1,089,158 shares
- Warrant Exercise Price: $0.51358 per share
- Warrant Terms: Exercisable six months after issuance; expire five and one-half years after issuance.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the entry into a Securities Purchase Agreement with institutional and accredited investors. This transaction resulted in the issuance of new equity securities and warrants, increasing the company's share count and providing immediate capital. The securities were sold in reliance on exemptions from registration under Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard representations and warranties typical for such transactions. The transaction was executed to raise capital, but the specific strategic use of proceeds is not detailed in this summary text.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and restrictions.
- Confirm the exercise timeline for the warrants (6-month vesting period) and their potential future dilution.
- Check subsequent filings for the actual use of the $1.25 million in proceeds.
- Note the discrepancy between the requested company name (Streamex Corp.) and the actual registrant (BioSig Technologies, Inc.).